Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $35
Pfizer (PFE) Receives a Buy From Jefferies
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Pfizer Analyst Ratings
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $36
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Erste Group Initiates Pfizer(PFE.US) With Hold Rating
Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
Citigroup Adjusts Price Target on Pfizer to $30 From $28, Maintains Neutral Rating
Pfizer Analyst Ratings
Daiwa Capital Upgrades Pfizer to Outperform, Raises Price Target to $34
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Argus Research Maintains Pfizer(PFE.US) With Hold Rating
UBS Group raised the target price of Pfizer to 31 dollars.